PARP抑制剂
BRCA突变
生殖系
化疗
癌症
顺铂
卡铂
癌症研究
作者
Richard T. Penson,Ricardo Villalobos Valencia,David Cibula,Nicoletta Colombo,Charles A. Leath,Mariusz Bidziński,Jae Weon Kim,Joo-Hyun Nam,Radoslaw Madry,Carlos Alberto Hernández,Paulo Alexandre Ribeiro Mora,Sang Young Ryu,Tsveta Milenkova,Elizabeth S. Lowe,Laura Barker,Giovanni Scambia
摘要
PURPOSEA phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resi...
科研通智能强力驱动
Strongly Powered by AbleSci AI